tiprankstipranks
TCR2 Therapeutics downgraded to Hold from Buy at Jefferies
The Fly

TCR2 Therapeutics downgraded to Hold from Buy at Jefferies

Jefferies analyst Kelly Shi downgraded TCR2 Therapeutics (TCRR) to Hold from Buy with a price target of $3, down from $18, after the company reached a definitive merger agreement under which Adaptimmune (ADAP). The all-stock transaction will create a new cell therapy company for solid tumors with TCR2 comprising 25% of the joint company, the analyst tells investors in a research note.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on TCRR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles